206115-40-4

Usage

Uses

Used in Organic Synthesis:
3-(tributylstannyl)-4-chloropyridine is used as a reagent in organic synthesis for facilitating various chemical transformations. Its unique structure allows it to participate in cross-coupling reactions, which are essential for constructing complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3-(tributylstannyl)-4-chloropyridine is utilized as a precursor in the development of new drugs. Its potential utility lies in its ability to be modified and incorporated into medicinal compounds that target specific biological pathways or receptors.
Used in Agrochemical Industry:
3-(tributylstannyl)-4-chloropyridine also finds application in the agrochemical industry, where it may serve as a starting material for the synthesis of new pesticides or other agrochemical products, contributing to the development of more effective and targeted crop protection agents.

Upstream product

• 626-61-9 4-Chloropyridine 
• 1461-22-9 tributyltin chloride 

Downstream Products

• 167167-28-4 methyl 5-acetyl-1H-pyrrole-2-carboxylate 
• 206115-68-6 5-Acetyl-4-(4-chloro-pyridin-3-yl)-1H-pyrrole-2-carboxylic acid methyl ester 
• 27353-36-2 4,4'-dichloro-3,3'-bipyridine 
• 638220-20-9 8-[3-(4-chloro-pyridin-3-yl)-phenyl]-6-(1-methanesulfonyl-1-methyl-ethyl)-quinoline 
• 244-82-6 benzo-[2,3]furo[3,2-c]pyridine 
• 444989-48-4 2-(4-chloropyridin-3-yl)-phenol 

Relevant academic research and scientific papers

8-(BIARYL) QUINOLINE PDE4 INHIBITORS

8-(biaryl) quinolines wherein the bi-aryl group at the 8-position is in a meta relationship to the quinoline group, are PDE4 inhibitors useful in the treatment of asthma, chronic bronchitis, chronic obstructive pulmonary disease, eosinophilic granuloma, psoriasis and other benign or malignant proliferative skin diseases, endotoxic shock, laminitis in horses, colic in horses, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, chronic obstructive pulmonary disease in animals, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis, ortherosclerosis, atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid arthritis, ankylosing spondylitis, transplant rejection, graft versus host disease, hypersecretion of gastric acid, bacterial, fungal induced sepsis, viral induced sepsis, fungal induced septic shock, viral induced septic shock, inflammation-mediated chronic tissue degeneration, cytokine-mediated chronic tissue degeneration, osteoarthritis, cancer, cachexia, muscle wasting, depression, memory impairment, tumour growth, or cancerous invasion of normal tissues.In another aspect, the present invention is directed to a method of enhancing cognition in a healthy subject comprising administering a safe cognition enhancing amount of phosphodiesterase-4 inhibitor. In particular, this invention is directed to a method of enhancing memory, learning, retention, recall, awareness and judgement in health subjects comprising administering a safe and cognition enhancing amount of a phosphodiesterase-4 inhibitor.